Drug Profile
Research programme: cancer therapeutics - Valerio Therapeutics
Alternative Names: BA-016; Zyxin targeted cancer therapeutics - Valerio Therapeutics; ZyxineLatest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator BioAlliance Pharma
- Developer Valerio Therapeutics
- Class
- Mechanism of Action Actin stimulants; Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Sep 2014 Discontinued - Preclinical for Cancer in France (unspecified route)
- 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
- 02 Feb 2011 Preclinical development is ongoing in France